To explore the clinical effect of alendronate combined with Jintiange capsules in the treatment of postmeno-pausal osteoporosis ( PMOP) . Methods:Ninety-eight cases of PMOP patients were randomly divided into three groups. The combina-tion treatment group (34 cases) was treated with alendronate tablets combined with Jintiange capsules, while the control group A (32 cases) and the control group B (32 cases) was respectively treated with alendronate tablets and Jintiange capsules, and the treatment course was six months. The changes of the clinical symptom score, bone mineral density ( BMD) , serum calcium, serum phosphorus, AKP, hepatorenal function and so on before and after the treatment were recorded. Results:After the six-month treatment, the clinical symptom score of the treatment group was much better than that in the two control groups(P<0. 05). BMD in the three groups was in-creased after the treatment(P<0. 05), and the increase in the treatment group was more notable than that in the two control groups(P<0. 05). Conclusion:Alendronate combined with Jintiange capsules can effectively improve BMD and relieve clinical symptoms in the patients with PMOP, which is worthy of promoted application.

Objective To investigate the rehabilitative effect of low frequency repetitive transcranial magnetic stimulation (rTMS) on convalescing patients with Broca's aphasia. MethodsTwenty-eight patients with Broca's aphasia recovering from cerebral infarction were randomly divided into a stimulation group and a control group with 14 subjects in each.Patients in the control group accepted conventional drugs,speech rehabilitation and sham stimulation,while patients in the stimulation group were in given low frequency rTMS in place of the sham stimulation.Their speech performance was evaluated using the China Rehabilitation Research Center's aphasia examination (CRRCAE) pre-stimulation,post-stimulation and 90 days later. ResultsCompared with before treatment and with the controls,the speaking scores of the stimulation group increased significantly after treatment and also 90 days later. ConclusionLow frequency rTMS can not only improve the speech performance of Broca's aphasia sufferers in the short term,but it also plays a lasting role.It may thus have clinical application for patients with Broca's aphasia.

Objecthe To equate the effects of recombinant human growth hormone (rhGH) on serum albumin lewis and intestinal mucosal morphology in rats with intracerebral hemorrhage. Methods A rat model of intracerebral hemorrhage was induced by autologous blood injection. Fifty-six SD rats were divided into sham-operation group (n =8), rhGH group (n =24; intraperitoneal injection of rhGH, 1 U/kg, once a day), and saline control group (n =24; intraperitoneal injection of equivalent normal saline, once a day). The rhGH and saline control groups were redivided into 1-, 7- and 14-day groups (n =8 in each group) after the procedure. The serum albumin concentration was detected at different time points in all groups. The changes of intestinal mucosal morphology were observed with Hematoxylin and Eosin (HE)staining and image analysis. Results Hie serum albumin lewis at all time points of intracerebral hemorrhage in the saline control group were all significantly lower than those in the sham-operation group (all P < 0. 01); The serum albumin level was increased gradually with the treatment process in the rhGH group, however, it was only significantly higher than the saline control group at day 14 (39.93 ±1.98 g/L νs. 37. 93 ±1.57 g/L) (P<0. 01). There were no significant differences between the rhGH group and the saline group in intestinal villus height and mucosal thickness at day 1 and 7 after intracerebral hemorrhage, however they were increased significantly at day 14 (P <0.01). The area of intestinal villi was reduced progressively at day 1, 7 and 14 after intracerebral hemorrhage, and with the treatment process the rhGH group was increased more progressively than the saline control group (P <0. 01). The depth of intestinal glands in the rhGH group was increased significantly than that in the saline control group (P <0. 01), but there was no significant difference at day 14; the density of glands in the rhGH group was significantly increased than that in the saline group at day 1 after intracerebral hemorrhage (P < 0. 01), and it was not increased significantly at day 7, however, it was not increased but decreased slightly at day 14. Conclusions The serum albumin level in rats with intracerebral hemorrhage was decreased significantly than that in the sham-operation group, and intracerebral hemorrhage could cause intestinal mucosal injury. rhGH increased the serum albumin level in rats with intracerebral hemorrhage. It might reduce intestinal mucosal injury to different degrees whether it was in the early or late intracerebral hemorrhage, and the late improvement was more significant. The improvement degree of rhGH on intestinal mucosal injury was positively correlated with the increased degrees of the serum albumin level.

BACKGROUND:An abroad study repoRed the distribution and expression of augmenter of liver regeneration(ALR)in the central nervous system.There are few literatures on how to prepare and evaluate ALR protein polyclonal antibody in recombinant rats,and how to construct prokaryotic expression vector.There are no repots concerning ALR in the central nervous system in China.OBJECTIVE:TO express ALR fusion protein in E coli BL21 and prepare and identify polyclonal antibody.METHODS:RNA was extracted from the hippocampus of Sprague Dawley rats.The prokaryotic expression plasmid pET28a-ALR was constructed and the positive recombinant plasmid was transformed into BL21.Protein ALR was expressed by inducing transformed BL21 with Isopropyl-β-D-thiogalactopyranoside(IPTG)and purified by Ni~(2+)affinity chromatography column after immune the rabbit for 4 times.the serum of rabbits was extracted from hear as polyclonal antibody.The titer and specificity of the rabbit's antiserum was respectively measured by ELISA and Western blotting The following parameters were measured:construction of prokaryotic expression plasmid pET26a-ALR;pET28a-ALR recombinant enzyme digestion evaluation;results of ELISA and Western-blotting.RESULTS AND CONCLUSION:Expecting bands were obtained by double enzyme digestion electrophoresis,respectively 5.3 kb and 0.4 kb.Nucleotide sequence analysis verified that prokaryotic expression vector pET28a-ALR was successfully constructed.The 19 ku fusion protein was successfuIly expressed.The titer of the antiserum measured by ELlSA could achieve 1:2 000 This indicated that antibody and purified recombinant ALR had a good reaction.and high titer.could meet the experimental require.Western blotting analysis proved that the antibody could identify the prokaryotic expression product of ALR.Prokaryotic expression system expressed ALR fusion protein,prepared and purified polyclonal antibody of ALR protein,and could meet the experimental require of ALR immunoblotting.

ObjectiveTo explore the expression levels of miRNA-153 and miRNA-223 in the serum of patients with Parkinson’s disease（PD）and their clinical value，as well as the correlation between the expression of miRNA-153 and miRNA-223 in the serum of PD patients and Hoehn-Yahr（H-Y）scales. 〖WTHZ〗Methods〖WTBZ〗The relative expression levels of serum miRNA-153 and miRNA-223 in 35 patients with PD（PD group）and 40 healthy people（healthy control group）were quantitatively detected. The H-Y scales of PD patients were evaluated. The results were analyzed. 〖WTHZ〗Results〖WTBZ〗The relative expression levels of serum miRNA-153 in PD group were significantly lower than that in healthy control group（t=5.71；P<0.01）. The relative expression levels of serum miRNA-223 in PD group were also significantly lower than that in healthy control group（t=6.07；P<0.01）. There was a negative correlation between the relative expression levels of serum miRNA-153 and H-Y scales in PD group（r=-0.4504，P<0.01）. 〖WTHZ〗Conclusion〖WTBZ〗Serum miRNA-153 and miRNA-223 may be used as biomarkers for the diagnosis of PD；serum miRNA-153 may become an indicator for evaluating the progress of PD.